Anthony Tak-Cheung Chan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5704051/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nasopharyngeal carcinoma. Lancet, The, 2019, 394, 64-80.	13.7	1,667
2	Nasopharyngeal carcinoma. Lancet, The, 2016, 387, 1012-1024.	13.7	1,045
3	Prospective Randomized Study of Intensity-Modulated Radiotherapy on Salivary Cland Function in Early-Stage Nasopharyngeal Carcinoma Patients. Journal of Clinical Oncology, 2007, 25, 4873-4879.	1.6	668
4	Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer. Journal of Clinical Oncology, 2004, 22, 4456-4462.	1.6	618
5	Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncology, The, 2015, 16, 645-655.	10.7	593
6	Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. International Journal of Radiation Oncology Biology Physics, 2006, 64, 47-56.	0.8	583
7	Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. Journal of Clinical Oncology, 2015, 33, 3356-3364.	1.6	579
8	A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2005, 97, 1532-1538.	6.3	567
9	Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer. New England Journal of Medicine, 2017, 377, 513-522.	27.0	531
10	Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma. Journal of Clinical Oncology, 2009, 27, 242-249.	1.6	487
11	Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1440-1450.	0.8	484
12	Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma. Journal of the National Cancer Institute, 2005, 97, 536-539.	6.3	449
13	Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing. Clinical Chemistry, 2013, 59, 211-224.	3.2	447
14	Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial. Journal of Clinical Oncology, 2002, 20, 2038-2044.	1.6	443
15	Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet, The, 1999, 353, 797-801.	13.7	436
16	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. Journal of Clinical Oncology, 2010, 28, 1660-1665.	1.6	424
17	Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal Carcinoma. Journal of the National Cancer Institute, 2002, 94, 1614-1619.	6.3	384
18	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18761-18768.	7.1	363

#	Article	IF	CITATIONS
19	Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma. Journal of Clinical Oncology, 2006, 24, 5414-5418.	1.6	346
20	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). Journal of Clinical Oncology, 2018, 36, 1412-1418.	1.6	324
21	Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncology, The, 2012, 13, 172-180.	10.7	291
22	Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma. Journal of Clinical Oncology, 2005, 23, 3568-3576.	1.6	277
23	A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 1995, 33, 569-577.	0.8	270
24	Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Reviews in Molecular Medicine, 2007, 9, 1-24.	3.9	266
25	What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. Journal of Clinical Oncology, 2017, 35, 498-505.	1.6	263
26	Nasopharyngeal carcinoma. Annals of Oncology, 2002, 13, 1007-1015.	1.2	257
27	Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy. Journal of Clinical Oncology, 2004, 22, 927-934.	1.6	255
28	Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene, 2006, 25, 1070-1080.	5.9	247
29	New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy. Journal of Clinical Oncology, 2009, 27, 446-452.	1.6	241
30	Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clinical Cancer Research, 2002, 8, 2595-604.	7.0	237
31	Comprehensive Proteomic Profiling Identifies Serum Proteomic Signatures for Detection of Hepatocellular Carcinoma and Its Subtypes. Clinical Chemistry, 2003, 49, 752-760.	3.2	228
32	Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nature Communications, 2017, 8, 14121.	12.8	227
33	Nasopharyngeal carcinoma: an evolving paradigm. Nature Reviews Clinical Oncology, 2021, 18, 679-695.	27.6	207
34	Thoracoscopic Talc Insufflation Versus Talc Slurry for Symptomatic Malignant Pleural Effusion. Annals of Thoracic Surgery, 1996, 62, 1655-1658.	1.3	205
35	How Successful Is High-Dose (≥60 GY) Reirradiation Using Mainly External Beams in Salvaging Local Failures of Nasopharyngeal Carcinoma?. International Journal of Radiation Oncology Biology Physics, 1998, 40, 897-913.	0.8	198
36	TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. International Journal of Cancer, 2009, 124, 644-652.	5.1	192

#	Article	IF	CITATIONS
37	Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). Oral Oncology, 2018, 77, 16-21.	1.5	189
38	<i>WNT5A</i> Exhibits Tumor-Suppressive Activity through Antagonizing the Wnt/β-Catenin Signaling, and Is Frequently Methylated in Colorectal Cancer. Clinical Cancer Research, 2008, 14, 55-61.	7.0	181
39	Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Research, 2003, 63, 2028-32.	0.9	181
40	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 840-859.	1.6	178
41	Plasma Epstein–Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Annals of Oncology, 2014, 25, 1204-1208.	1.2	175
42	Nasopharyngeal carcinoma. Annals of Oncology, 2010, 21, vii308-vii312.	1.2	174
43	Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23, vii83-vii85.	1.2	172
44	Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group. Cancer, 2004, 101, 300-306.	4.1	167
45	Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Journal of Clinical Oncology, 2012, 30, 3361-3367.	1.6	167
46	Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study. Head and Neck, 2003, 25, 864-872.	2.0	165
47	Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncology, The, 2015, 16, 208-220.	10.7	161
48	Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein–Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients. Cancer Research, 2013, 73, 1676-1688.	0.9	159
49	Survival outcome of patients with nasopharyngeal carcinoma with first local failure: A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head and Neck, 2005, 27, 397-405.	2.0	157
50	Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer, 2003, 98, 288-291.	4.1	154
51	Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Annals of Oncology, 2004, 15, 1661-1666.	1.2	153
52	Preliminary results of trial NPCâ€0501 evaluating the therapeutic gain by changing from concurrentâ€adjuvant to inductionâ€concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer, 2015, 121, 1328-1338.	4.1	152
53	Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2006, 66, 142-151.	0.8	151
54	An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. Clinical Cancer Research, 2013, 19, 2208-2215.	7.0	149

#	Article	IF	CITATIONS
55	Study of Serum Haptoglobin and Its Glycoforms in the Diagnosis of Hepatocellular Carcinoma:  A Glycoproteomic Approach. Journal of Proteome Research, 2006, 5, 2691-2700.	3.7	147
56	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. Journal of Clinical Oncology, 2018, 36, 3091-3100.	1.6	147
57	A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Investigational New Drugs, 2008, 26, 169-173.	2.6	142
58	A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer. Clinical Cancer Research, 2014, 20, 5009-5022.	7.0	139
59	Early detection of nasopharyngeal carcinoma by plasma Epsteinâ€Barr virus DNA analysis in a surveillance program. Cancer, 2013, 119, 1838-1844.	4.1	137
60	The Tumor Suppressor UCHL1 Forms a Complex with p53/MDM2/ARF to Promote p53 Signaling and Is Frequently Silenced in Nasopharyngeal Carcinoma. Clinical Cancer Research, 2010, 16, 2949-2958.	7.0	136
61	Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology, 2008, 48, 508-518.	7.3	134
62	Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clinical Cancer Research, 2003, 9, 3254-9.	7.0	132
63	Eight-Signature Classifier for Prediction of Nasopharyngeal Carcinoma Survival. Journal of Clinical Oncology, 2011, 29, 4516-4525.	1.6	131
64	Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in Tumors. Journal of Clinical Oncology, 2004, 22, 1373-1381.	1.6	129
65	Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. Clinical Cancer Research, 2018, 24, 1824-1833.	7.0	128
66	Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA. Journal of Clinical Oncology, 2004, 22, 3053-3060.	1.6	125
67	Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. International Journal of Radiation Oncology Biology Physics, 2000, 48, 1311-1322.	0.8	120
68	Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v187-v189.	1.2	120
69	The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene, 2007, 26, 934-944.	5.9	119
70	Epigenetic silencing of a Ca ²⁺ -regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12353-12358.	7.1	118
71	Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy. Annals of Surgical Oncology, 2008, 15, 1008-1014.	1.5	117
72	KRAB Zinc Finger Protein ZNF382 Is a Proapoptotic Tumor Suppressor That Represses Multiple Oncogenes and Is Commonly Silenced in Multiple Carcinomas. Cancer Research, 2010, 70, 6516-6526.	0.9	116

#	Article	IF	CITATIONS
73	Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5115-E5124.	7.1	114
74	Analysis of Epstein–Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. Journal of General Virology, 2006, 87, 2885-2890.	2.9	113
75	Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer, 2005, 103, 22-31.	4.1	112
76	Primary Nasopharyngeal Carcinoma: Diagnostic Accuracy of MR Imaging versus that of Endoscopy and Endoscopic Biopsy. Radiology, 2011, 258, 531-537.	7.3	112
77	A phase II study of concurrent cetuximab–cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Annals of Oncology, 2012, 23, 1287-1292.	1.2	111
78	Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene, 2007, 26, 7490-7498.	5.9	106
79	CTL Control of EBV in Nasopharyngeal Carcinoma (NPC): EBV-Specific CTL Responses in the Blood and Tumors of NPC Patients and the Antigen-Processing Function of the Tumor Cells. Journal of Immunology, 2000, 165, 573-582.	0.8	105
80	Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein–Barr Virus DNA and Anti-Epstein–Barr Viral Capsid Antigen IgA Antibody. Clinical Chemistry, 2004, 50, 339-345.	3.2	105
81	Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2006, 66, 714-720.	0.8	105
82	Integration of albumin–bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1300-1306.	2.8	103
83	Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions. Cancer Science, 2008, 99, 1311-1318.	3.9	102
84	A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiotherapy and Oncology, 2011, 98, 15-22.	0.6	102
85	Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Annals of Oncology, 2011, 22, 1280-1287.	1.2	102
86	The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer, 1998, 82, 1003-1012.	4.1	101
87	A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. European Journal of Cancer, 1998, 34, 2027-2031.	2.8	101
88	Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Annals of Oncology, 2006, 17, 1083-1089.	1.2	99
89	<i>CMTM3</i> , Located at the Critical Tumor Suppressor Locus 16q22.1, Is Silenced by CpG Methylation in Carcinomas and Inhibits Tumor Cell Growth through Inducing Apoptosis. Cancer Research, 2009, 69, 5194-5201.	0.9	95
90	The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Laboratory Investigation, 2007, 87, 644-650.	3.7	93

#	Article	IF	CITATIONS
91	Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiotherapy and Oncology, 2012, 104, 300-304.	0.6	93
92	OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation. PLoS ONE, 2008, 3, e2990.	2.5	92
93	The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/β-catenin signaling and silenced in common carcinomas. Oncogene, 2012, 31, 3901-3912.	5.9	92
94	Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Scientific Reports, 2016, 6, 26591.	3.3	90
95	Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. Oral Oncology, 2016, 53, 10-16.	1.5	86
96	A new prognostic histopathologic classification of nasopharyngeal carcinoma. Chinese Journal of Cancer, 2016, 35, 41.	4.9	83
97	A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein–Barr virus DNA as a biomarker of efficacy. Cancer Chemotherapy and Pharmacology, 2008, 62, 59-64.	2.3	82
98	The impact of ¹⁸ F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. British Journal of Radiology, 2008, 81, 291-298.	2.2	82
99	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 340-347.	2.8	75
100	Novel Intertypic Recombinants of Epstein-Barr Virus in the Chinese Population. Journal of Virology, 2000, 74, 1544-1548.	3.4	71
101	Epigenetic disruption of interferon-Î ³ response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene, 2008, 27, 5267-5276.	5.9	71
102	WNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biology and Therapy, 2010, 10, 617-624.	3.4	71
103	Update on the Management and Therapeutic Monitoring of Advanced Nasopharyngeal Cancer. Hematology/Oncology Clinics of North America, 2008, 22, 1267-1278.	2.2	69
104	Persistent Aberrations in Circulating DNA Integrity after Radiotherapy Are Associated with Poor Prognosis in Nasopharyngeal Carcinoma Patients. Clinical Cancer Research, 2008, 14, 4141-4145.	7.0	68
105	STAT3 activation contributes directly to Epsteinâ€Barr virus–mediated invasiveness of nasopharyngeal cancer cells <i>in vitro</i> . International Journal of Cancer, 2009, 125, 1884-1893.	5.1	67
106	Consensus recommendations for management of head and neck cancer in Asian countries: A review of international guidelines. Oral Oncology, 2013, 49, 872-877.	1.5	67
107	Dose–response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: A study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). Radiotherapy and Oncology, 2006, 79, 27-33.	0.6	66
108	Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis, 2009, 30, 2085-2094.	2.8	66

#	Article	IF	CITATIONS
109	Clinical Significance of Cytokeratin 20-Positive Circulating Tumor Cells Detected by a Refined Immunomagnetic Enrichment Assay in Colorectal Cancer Patients. Clinical Cancer Research, 2009, 15, 1005-1012.	7.0	65
110	The Epigenetic Modifier PRDM5 Functions as a Tumor Suppressor through Modulating WNT/β-Catenin Signaling and Is Frequently Silenced in Multiple Tumors. PLoS ONE, 2011, 6, e27346.	2.5	64
111	Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. In Vivo, 2005, 19, 237-45.	1.3	64
112	Radiotherapy for nasopharyngeal carcinoma—transition from two-dimensional to three-dimensional methods. Radiotherapy and Oncology, 2004, 73, 163-172.	0.6	60
113	Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology, 2007, 45, 1382-1389.	7.3	60
114	Quantitative Analysis of the Transrenal Excretion of Circulating EBV DNA in Nasopharyngeal Carcinoma Patients. Clinical Cancer Research, 2008, 14, 4809-4813.	7.0	60
115	DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. British Journal of Cancer, 2009, 100, 663-669.	6.4	60
116	Integrating postradiotherapy plasma Epstein–Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Annals of Oncology, 2020, 31, 769-779.	1.2	60
117	Prevention of Hepatitis B Virus Reactivation in Patients With Nasopharyngeal Carcinoma With Lamivudine. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 379-384.	1.3	59
118	Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology, 2002, 41, 144-151.	2.9	58
119	EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-Specific CD4+Cytotoxic T Cell Recognition of EBV-Transformed B Cell Lines. Journal of Immunology, 2008, 180, 1643-1654.	0.8	58
120	The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Investigational New Drugs, 2010, 28, 413-420.	2.6	58
121	The Metalloprotease ADAMTS8 Displays Antitumor Properties through Antagonizing EGFR–MEK–ERK Signaling and Is Silenced in Carcinomas by CpG Methylation. Molecular Cancer Research, 2014, 12, 228-238.	3.4	58
122	Multimodality treatment of primary lymphoepithelioma-like carcinoma of the lung. Cancer, 1998, 83, 925-929.	4.1	56
123	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Investigational New Drugs, 2010, 28, 107-114.	2.6	56
124	Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in in in inflammatory NF-1°B activation and immune escape. Nature Communications, 2021, 12, 4193.	12.8	56
125	Quantification and Utility of Monosialylated α-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma with Nondiagnostic Serum Total α-Fetoprotein. Clinical Chemistry, 2002, 48, 1021-1027.	3.2	55
126	Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma—correlation with excision repair cross-complementing-1 polymorphisms. Annals of Oncology, 2009, 20, 1854-1859.	1.2	55

#	Article	IF	CITATIONS
127	Advanced proteomic technologies for cancer biomarker discovery. Expert Review of Proteomics, 2009, 6, 123-134.	3.0	55
128	Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene, 2011, 30, 1127-1134.	5.9	55
129	Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. Cancer Chemotherapy and Pharmacology, 1996, 38, 466-470.	2.3	54
130	Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. International Journal of Radiation Oncology Biology Physics, 1999, 43, 261-271.	0.8	53
131	Liver Resection after Irinotecan, 5-Fluorouracil, and Folinic Acid for Patients with Unresectable Colorectal Liver Metastases: A Multicenter Phase II Study by the Cancer Therapeutic Research Group. Medical Oncology, 2005, 22, 303-312.	2.5	53
132	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer, 2012, 118, 3984-3992.	4.1	53
133	Frequent epigenetic silencing of <i>protocadherin 10</i> by methylation in multiple haematologic malignancies. British Journal of Haematology, 2007, 136, 829-832.	2.5	52
134	Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncology, The, 2009, 10, 1086-1092.	10.7	52
135	Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics, 2015, 7, 155-173.	2.1	52
136	Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. Nature Communications, 2019, 10, 3256.	12.8	52
137	Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. Annals of Oncology, 2019, 30, 977-982.	1.2	52
138	Pathogenesis and treatment of nasopharyngeal carcinoma. Seminars in Oncology, 2004, 31, 794-801.	2.2	51
139	Dosimetric Comparison Between 2-Dimensional Radiation Therapy and Intensity Modulated Radiation Therapy in Treatment of Advanced T-Stage Nasopharyngeal Carcinoma: To Treat Less or More in the Planning Organ-At-Risk Volume of the Brainstem and Spinal Cord. Medical Dosimetry, 2007, 32, 263-270.	0.9	51
140	Targeting tumor hypoxia in nasopharyngeal carcinoma. Head and Neck, 2013, 35, 133-145.	2.0	51
141	Detection of Nasopharyngeal Carcinoma by MR Imaging: Diagnostic Accuracy of MRI Compared with Endoscopy and Endoscopic Biopsy Based on Long-Term Follow-Up. American Journal of Neuroradiology, 2015, 36, 2380-2385.	2.4	51
142	A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 1999, 44, 307-311.	2.3	50
143	Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Letters, 2007, 253, 74-88.	7.2	50
144	Nasopharyngeal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv123-iv125.	1.2	49

#	Article	IF	CITATIONS
145	Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. The Cochrane Library, 2006, , CD004329.	2.8	48
146	A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Oncogene, 2011, 30, 1923-1935.	5.9	48
147	Applicability of albuminâ€bilirubinâ€based Japan integrated staging score in hepatitis Bâ€associated hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1766-1772.	2.8	47
148	Incorporating albumin–bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 221-228.	2.8	47
149	Disparity of sensitivities in detection of radiation-naÃ ⁻ ve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2. Clinical Cancer Research, 2003, 9, 3431-4.	7.0	47
150	Investigation into the Origin and Tumoral Mass Correlation of Plasma Epstein–Barr Virus DNA in Nasopharyngeal Carcinoma. Clinical Chemistry, 2005, 51, 2192-2195.	3.2	46
151	Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. Oral Oncology, 2019, 88, 124-130.	1.5	46
152	Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncology Reports, 2008, 20, 89-98.	2.6	46
153	A Novel 19q13 Nucleolar Zinc Finger Protein Suppresses Tumor Cell Growth through Inhibiting Ribosome Biogenesis and Inducing Apoptosis but Is Frequently Silenced in Multiple Carcinomas. Molecular Cancer Research, 2012, 10, 925-936.	3.4	44
154	FEZF2 , a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. Carcinogenesis, 2013, 34, 1984-1993.	2.8	44
155	Quantitative relationship of the circulating tumor burden assessed by reverse transcription-polymerase chain reaction for cytokeratin 19 mRNA in peripheral blood of colorectal cancer patients with Dukes' stage, serum carcinoembryonic antigen level and tumor progression. Cancer Letters, 2001, 162, 65-73.	7.2	43
156	Effect of age and disease on taste perception. Journal of Pain and Symptom Management, 2004, 28, 28-34.	1.2	43
157	Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β-catenin and AKT signaling but frequently methylated in common carcinomas. Cellular and Molecular Life Sciences, 2014, 71, 2179-2192.	5.4	43
158	Clinical utility of plasma Epsteinâ€Barr virus DNA and <i>ERCC1</i> single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer, 2015, 121, 2720-2729.	4.1	43
159	Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Supportive Care in Cancer, 2011, 19, 1625-1635.	2.2	42
160	Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Review of Anticancer Therapy, 2006, 6, 383-394.	2.4	41
161	CXCR6 and CCR5 Localize T Lymphocyte Subsets in Nasopharyngeal Carcinoma. American Journal of Pathology, 2012, 180, 1215-1222.	3.8	41
162	Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study. Clinical Cancer Research, 2018, 24, 1030-1037.	7.0	41

#	Article	IF	CITATIONS
163	Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Investigational New Drugs, 2010, 28, 326-333.	2.6	40
164	Current treatment of nasopharyngeal carcinoma. European Journal of Cancer, 2011, 47, S302-S303.	2.8	40
165	CD4 and CD8 T cell responses to tumour-associated Epstein–Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunology, Immunotherapy, 2008, 57, 963-975.	4.2	38
166	Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. Investigational New Drugs, 2013, 31, 567-575.	2.6	38
167	Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data. BMC Cancer, 2017, 17, 8.	2.6	38
168	Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver International, 2017, 37, 280-289.	3.9	38
169	Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. Journal of Medical Virology, 2002, 67, 359-363.	5.0	37
170	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. Journal of the National Cancer Institute, 2017, 109, .	6.3	37
171	MR Imaging Criteria for the Detection of Nasopharyngeal Carcinoma: Discrimination of Early-Stage Primary Tumors from Benign Hyperplasia. American Journal of Neuroradiology, 2018, 39, 515-523.	2.4	37
172	NPCâ€0501 trial on the value of changing chemoradiotherapy sequence, replacing 5â€fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. Cancer, 2020, 126, 3674-3688.	4.1	37
173	An Intensive Surveillance Program Detected a High Incidence of Hepatocellular Carcinoma Among Hepatitis B Virus Carriers With Abnormal Alpha-Fetoprotein Levels or Abdominal Ultrasonography Results. Journal of Clinical Oncology, 2005, 23, 8041-8047.	1.6	36
174	Clinical Studies of Immunomodulatory Activities of Yunzhi-Danshen in Patients with Nasopharyngeal Carcinoma. Journal of Alternative and Complementary Medicine, 2006, 12, 771-776.	2.1	36
175	A small molecule inhibitor of NF-κB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Letters, 2010, 287, 23-32.	7.2	36
176	Application of Classification Tree and Neural Network Algorithms to the Identification of Serological Liver Marker Profiles for the Diagnosis of Hepatocellular Carcinoma. Oncology, 2001, 61, 275-283.	1.9	35
177	Plasma Osteopontin, Hypoxia, and Response to Radiotherapy in Nasopharyngeal Cancer. Clinical Cancer Research, 2008, 14, 7080-7087.	7.0	35
178	Distinguishing early-stage nasopharyngeal carcinoma from benign hyperplasia using intravoxel incoherent motion diffusion-weighted MRI. European Radiology, 2019, 29, 5627-5634.	4.5	35
179	Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas. Theranostics, 2018, 8, 61-77.	10.0	33
180	HLA-A11-Restricted Epitope Polymorphism among Epstein-Barr Virus Strains in the Highly HLA-A11-Positive Chinese Population: Incidence and Immunogenicity of Variant Epitope Sequences. Journal of Virology, 2003, 77, 11507-11516.	3.4	32

#	Article	IF	CITATIONS
181	High-density lipoprotein cholesterol as a predictor of poor survival in patients with nasopharyngeal carcinoma. Oncotarget, 2016, 7, 42978-42987.	1.8	32
182	Nasopharyngeal Cancers: Which Method Should be Used to Measure these Irregularly Shaped Tumors on Cross-Sectional Imaging?. International Journal of Radiation Oncology Biology Physics, 2007, 69, 148-154.	0.8	31
183	Impaired Deoxyribonuclease I Activity in Patients with Inflammatory Bowel Diseases. Autoimmune Diseases, 2011, 2011, 1-5.	0.6	31
184	Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). Investigational New Drugs, 2015, 33, 985-991.	2.6	31
185	Role of α-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. Future Oncology, 2009, 5, 889-899.	2.4	30
186	Preclinical evaluation of the mTOR–PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Letters, 2014, 343, 24-32.	7.2	30
187	Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus–Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma. Cancer Immunology Research, 2015, 3, 1138-1147.	3.4	30
188	Quantitative Analysis of Pleural Fluid Cell-free DNA as a Tool for the Classification of Pleural Effusions. Clinical Chemistry, 2003, 49, 740-745.	3.2	29
189	An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation. Biochemical Pharmacology, 2010, 79, 1772-1780.	4.4	28
190	Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Investigational New Drugs, 2011, 29, 1123-1131.	2.6	28
191	Epstein-Barr Virus as a Paradigm in Nasopharyngeal Cancer: From Lab to Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 149-153.	3.8	28
192	Early tumour response and treatment toxicity after hyperfractionated radiotherapy in nasopharyngeal carcinoma. British Journal of Radiology, 1996, 69, 241-248.	2.2	27
193	Reduced Plasma RNA Integrity in Nasopharyngeal Carcinoma Patients. Clinical Cancer Research, 2006, 12, 2512-2516.	7.0	27
194	Tumor-Specific Methylation of the 8p22 Tumor Suppressor Gene DLC1 is an Epigenetic Biomarker for Hodgkin, Nasal NK/T-Cell and Other Types of Lymphomas. Epigenetics, 2007, 2, 15-21.	2.7	27
195	Barriers to clinical trial recruitment in head and neck cancer. Oral Oncology, 2015, 51, 203-211.	1.5	27
196	Proteomic Comparison of Nasopharyngeal Cancer Cell Lines C666-1 and NP69 Identifies Down-Regulation of Annexin II and β2-Tubulin for Nasopharyngeal Carcinoma. Archives of Pathology and Laboratory Medicine, 2008, 132, 675-683.	2.5	27
197	A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II) Tj ETQq1	1 0.78431 4.1	4 rgBT /Ovei
198	TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of	1.8	26

nasopharyngeal carcinoma cells. Oncology Letters, 2015, 9, 569-574. 198

1.8 26

#	Article	IF	CITATIONS
199	VIDEO-ASSISTED THORACOSCOPIC WEDGE RESECTIONS OF PULMONARY METASTATIC OSTEOSARCOMA: SHOULD IT BE PERFORMED?. ANZ Journal of Surgery, 1995, 65, 737-739.	0.7	25
200	The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong. Pharmacoeconomics, 2001, 19, 947-953.	3.3	25
201	Treatment strategy and clinical experience. Seminars in Cancer Biology, 2002, 12, 497-504.	9.6	25
202	Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma—a prognostic evaluation and correlation with hypoxia inducible factor 1α and vascular endothelial growth factor. Oral Oncology, 2007, 43, 373-378.	1.5	25
203	Clinical Significance of Frizzled Homolog 3 Protein in Colorectal Cancer Patients. PLoS ONE, 2013, 8, e79481.	2.5	25
204	Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma. Scientific Reports, 2018, 8, 8010.	3.3	25
205	Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. Cancer, 2001, 91, 2369-2377.	4.1	24
206	Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. Investigational New Drugs, 2013, 31, 1399-1408.	2.6	24
207	Prospective evaluation of plasma Epstein–Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. British Journal of Cancer, 2018, 118, 1051-1055.	6.4	24
208	Controversies in the management of locoregionally advanced nasopharyngeal carcinoma. Current Opinion in Oncology, 1998, 10, 219-225.	2.4	23
209	Investigational drugs for nasopharyngeal carcinoma. Expert Opinion on Investigational Drugs, 2017, 26, 677-685.	4.1	23
210	Transdermal fentanyl for severe cancer-related pain. Palliative Medicine, 1997, 11, 233-239.	3.1	22
211	Nasal lymphoma: Results of local radiotherapy with or without chemotherapy. , 1997, 19, 251-259.		22
212	Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes. Cancer Chemotherapy and Pharmacology, 1999, 44, 124-130.	2.3	22
213	Effects of Patupilone (Epothilone B; EPO906), a Novel Chemotherapeutic Agent, in Hepatocellular Carcinoma: An in vitro Study. Oncology, 2006, 71, 292-296.	1.9	22
214	Transarterial Ethanol Ablation of Hepatocellular Carcinoma with Lipiodol–Ethanol Mixture: Phase II Study. Journal of Vascular and Interventional Radiology, 2008, 19, 95-103.	0.5	22
215	Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. British Journal of Cancer, 2011, 104, 1000-1006.	6.4	22
216	International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chinese Journal of Cancer, 2014, 33, 481-91.	4.9	22

#	Article	IF	CITATIONS
217	Increased incidence of tongue cancer after primary radiotherapy for nasopharyngeal carcinoma—the possibility of radiation carcinogenesis. European Journal of Cancer, 1999, 35, 219-225.	2.8	21
218	CD4 + T-Cell Responses to Epstein-Barr Virus Nuclear Antigen EBNA1 in Chinese Populations Are Highly Focused on Novel C-Terminal Domain-Derived Epitopes. Journal of Virology, 2006, 80, 8263-8266.	3.4	21
219	Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. Investigational New Drugs, 2011, 29, 401-410.	2.6	21
220	K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV)—associated nasopharyngeal carcinoma cells. Investigational New Drugs, 2012, 30, 48-58.	2.6	21
221	Prospective validation of serum CYFRA 21-1, ?-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy. Cancer, 2004, 101, 776-781.	4.1	20
222	Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 6701.	3.3	20
223	Pharmacoproteomics Study of Cetuximab in Nasopharyngeal Carcinoma. Journal of Proteome Research, 2006, 5, 3260-3267.	3.7	20
224	Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. Biochemical Pharmacology, 2010, 79, 842-852.	4.4	20
225	Application of the international prognostic index in a study of chinese patients with non-hodgkin's lymphoma and a high incidence of primary extranodal lymphoma. , 1998, 82, 2439-2448.		19
226	The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma. Oral Oncology, 2008, 44, 1067-1072.	1.5	19
227	Novel therapeutic target for head and neck squamous cell carcinoma. Anti-Cancer Drugs, 2011, 22, 665-673.	1.4	19
228	Gemcitabine: a game changer in nasopharyngeal carcinoma. Lancet, The, 2016, 388, 1853-1854.	13.7	19
229	Biologics and biosimilars: what, why and how?. ESMO Open, 2017, 2, e000180.	4.5	19
230	Patientâ€specific quality assurance using machine log files analysis for stereotactic body radiation therapy (SBRT). Journal of Applied Clinical Medical Physics, 2020, 21, 179-187.	1.9	19
231	Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma-frequency of specific banding patterns at non-diagnostic serum levels. British Journal of Cancer, 1996, 73, 985-988.	6.4	18
232	A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer, 2000, 89, 543-550.	4.1	18
233	A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN) Journal of Clinical Oncology, 2012, 30, 5502-5502.	1.6	18
234	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. Clinical and Translational Radiation Oncology, 2022, 32, 59-68.	1.7	18

#	Article	IF	CITATIONS
235	Quantitative Analysis of Cell-Free Epstein-Barr Virus DNA in Plasma of Patients with Nonnasopharyngeal Head and Neck Carcinomas. Clinical Cancer Research, 2004, 10, 1726-1732.	7.0	17
236	Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. Investigational New Drugs, 2011, 29, 1241-1252.	2.6	17
237	Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer—a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. Annals of Oncology, 2017, 28, 1576-1581.	1.2	17
238	Germ cell tumors express a specific alpha-fetoprotein variant detectable by isoelectric focusing. Cancer, 1995, 75, 1663-1668.	4.1	16
239	Inhibition of apoptosis in human laryngeal cancer cells by E6 and E7 oncoproteins of human papillomavirus 16. Journal of Cellular Biochemistry, 2008, 103, 1125-1143.	2.6	16
240	Use of antiviral therapy in surveillance: impact on outcome of hepatitis Bâ€related hepatocellular carcinoma. Liver International, 2012, 32, 271-278.	3.9	16
241	Epstein-Barr Virus-Induced Epigenetic Pathogenesis of Viral-Associated Lymphoepithelioma-Like Carcinomas and Natural Killer/T-Cell Lymphomas. Pathogens, 2018, 7, 63.	2.8	16
242	Longitudinal Colour Doppler Study of Superficial Lymph Nodes in Non-Hodgkin's Lymphoma Patients on Chemotherapy. Clinical Radiology, 2000, 55, 110-113.	1.1	15
243	Technical evaluation of MALDI-TOF mass spectrometry for quantitative proteomic profiling matrix formulation and application. Clinical Proteomics, 2004, 1, 259-270.	2.1	15
244	Distribution of Cell-Free and Cell-Associated Epstein–Barr Virus (EBV) DNA in the Blood of Patients with Nasopharyngeal Carcinoma and EBV-Associated Lymphoma. Clinical Chemistry, 2004, 50, 1842-1845.	3.2	15
245	Phase II Randomized Study Comparing the Toxicity Profile of Gemcitabine plus Cisplatin with Gemcitabine plus Oral Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer. Oncology, 2005, 68, 485-492.	1.9	15
246	Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemotherapy and Pharmacology, 2006, 59, 295-300.	2.3	15
247	Isolated Tumor Cells and Circulating CK20 mRNA in pN0 Colorectal Cancer Patients. International Journal of Surgical Pathology, 2008, 16, 119-126.	0.8	15
248	Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC). American Journal of Cancer Research, 2015, 5, 1496-506.	1.4	15
249	Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression. Biomedicine and Pharmacotherapy, 2005, 59, S268-S271.	5.6	14
250	Applicability of <scp>BALAD</scp> score in prognostication of hepatitis <scp>B</scp> â€related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1529-1535.	2.8	14
251	The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma. Current Opinion in Oncology, 2020, 32, 187-195.	2.4	14
252	Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients Journal of Clinical Oncology, 2020, 38, 6523-6523.	1.6	14

#	Article	IF	CITATIONS
253	Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein. Clinical Chemistry, 2002, 48, 1021-7.	3.2	14
254	A retrospective study of the use of cisplatinum-5-fluorouracil neoadjuvant chemotherapy in cervical-node-positive nasopharyngeal carcinoma (NPC). European Journal of Cancer Part B, Oral Oncology, 1995, 31, 373-379.	0.9	13
255	False-Negative Rate of Abdominal Sonography for Detecting Hepatocellular Carcinoma in Patients with Hepatitis B and Elevated Serum α-Fetoprotein Levels. American Journal of Roentgenology, 2004, 183, 453-458.	2.2	13
256	Nuclear Â-catenin and Ki-67 expression in choriocarcinoma and its pre-malignant form. Journal of Clinical Pathology, 2006, 59, 387-392.	2.0	13
257	Dynamic Changes of Post-Radiotherapy Plasma Epstein–Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer. Clinical Cancer Research, 2021, 27, 2827-2836.	7.0	13
258	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT) Journal of Clinical Oncology, 2017, 35, 6002-6002.	1.6	13
259	Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma. Cancer Chemotherapy and Pharmacology, 1998, 42, 247-249.	2.3	12
260	The use of brush cytology and directed biopsies for the detection of nasopharyngeal carcinoma and precursor lesions. Head and Neck, 2001, 23, 637-645.	2.0	12
261	Comparison of Protocols for Extracting Circulating DNA and RNA from Maternal Plasma. Clinical Chemistry, 2005, 51, 2209-2210.	3.2	12
262	A Split-organ Delineation Approach for Dose Optimisation for Intensity-modulated Radiotherapy for Advanced T-stage Nasopharyngeal Carcinoma. Clinical Oncology, 2008, 20, 134-141.	1.4	12
263	Dosimetric Comparison of Intensity-Modulated Stereotactic Radiotherapy With Other Stereotactic Techniques for Locally Recurrent Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 79, 71-79.	0.8	12
264	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2013, 71, 1417-1425.	2.3	12
265	Elucidating the prognostic significance of <scp><i>KRAS</i></scp> , <scp><i>NRAS</i></scp> , <scp><i>BRAF</i></scp> and <scp><i>PIK3CA</i></scp> mutations in <scp>C</scp> hinese patients with metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 160-169.	1.1	12
266	Tumor Suppression of Ras GTPase-Activating Protein RASA5 through Antagonizing Ras Signaling Perturbation in Carcinomas. IScience, 2019, 21, 1-18.	4.1	12
267	Germline Polymorphisms and Length of Survival of Nasopharyngeal Carcinoma: An Exomeâ€Wide Association Study in Multiple Cohorts. Advanced Science, 2020, 7, 1903727.	11.2	12
268	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Journal of Clinical Oncology, 2008, 26, 6055-6055.	1.6	12
269	Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers. Cancer Treatment Reviews, 2022, 105, 102361.	7.7	12
270	Pseudomembranous colitis complicating chemotherapy. Lancet, The, 1992, 339, 192-193.	13.7	11

Anthony Tak-Cheung Chan

#	Article	IF	CITATIONS
271	Rapid healing of an indolent leg ulcer with topical rhGM SF. Australian and New Zealand Journal of Medicine, 1996, 26, 420-421.	0.5	11
272	Carbamazepine-induced lymphadenopathy mimicking Ki-1 (CD30 +) T-cell lymphoma. Pathology, 1997, 29, 64-66.	0.6	11
273	A prospective study of pre-treatment cell kinetics and clinical outcome in nasopharyngeal carcinoma. Radiotherapy and Oncology, 2003, 69, 53-62.	0.6	11
274	Nasopharyngeal Cancer. Cancer Treatment and Research, 2004, 114, 275-293.	0.5	11
275	Human Papillomavirus DNA Detection in Menstrual Blood from Patients with Cervical Intraepithelial Neoplasia and Condyloma Acuminatum. Journal of Clinical Microbiology, 2010, 48, 709-713.	3.9	11
276	FGF8b oncogene mediates proliferation and invasion of Epstein–Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation. Oncogene, 2011, 30, 1518-1530.	5.9	11
277	Intermittent versus continuous erlotinib with concomitant modified "XELOX―(q3W) in firstâ€line treatment of metastatic colorectal cancer. Cancer, 2013, 119, 4145-4153.	4.1	11
278	Controversies in the systemic treatment of Nasopharyngeal carcinoma. Oral Oncology, 2014, 50, 785-790.	1.5	11
279	Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma. American Journal of Cancer Research, 2014, 4, 789-800.	1.4	11
280	Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC). American Journal of Cancer Research, 2015, 5, 3588-99.	1.4	11
281	Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer. Anti-Cancer Drugs, 2002, 13, 655-662.	1.4	10
282	Adjuvant Chemoradiation for Gastric Cancer: Experience in the Chinese Population. Clinical Oncology, 2007, 19, 333-340.	1.4	10
283	The effect of centrifugation on circulating mRNA quantitation opens up a new scenario in expression profiling from patients with metastatic colorectal cancer. Clinical Biochemistry, 2007, 40, 1277-1284.	1.9	10
284	Nasopharyngeal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2008, 19, ii81-ii82.	1.2	10
285	Phase II study of TAS â€106 in patients with platinumâ€failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. Cancer Medicine, 2013, 2, 351-359.	2.8	10
286	Jagged 2 silencing inhibits motility and invasiveness of colorectal cancer cell lines. Oncology Letters, 2016, 12, 5193-5198.	1.8	10
287	Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant Profiles. Clinical Chemistry, 2020, 66, 598-605.	3.2	10
288	Durability of the parotidâ€sparing effect of intensityâ€modulated radiotherapy (<scp>IMRT</scp>) in early stage nasopharyngeal carcinoma: A 15â€year followâ€up of a randomized prospective study of <scp>IMRT</scp> versus twoâ€dimensional radiotherapy. Head and Neck, 2021, 43, 1711-1720.	2.0	10

#	Article	IF	CITATIONS
289	Differential expression of the suppressor PML and Ki-67 identifies three subtypes of human nasopharyngeal carcinoma. European Journal of Cancer, 2002, 38, 1600-1606.	2.8	9
290	Nuclear ??-Catenin Expression Is Rare and its Potential Association With Short Survival in Colorectal Signet-Ring Cell Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2005, 13, 248-251.	1.2	9
291	A Broadly Adaptive Array of Dose-Constraint Templates for Planning of Intensity-Modulated Radiation Therapy for Advanced T-Stage Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2009, 74, 21-28.	0.8	9
292	Phase II Study of Concurrent and Adjuvant Chemotherapy with Intensity Modulated Radiation Therapy (IMRT) or Three-dimensional Conformal Radiotherapy (3D-CRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer (NPC)[RTOG 0615]: Preliminary Toxicity Report. International Journal of Radiation Oncology Biology Physics, 2010, 78, S103-S104.	0.8	9
293	Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. Investigational New Drugs, 2013, 31, 30-38.	2.6	9
294	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. Oncologist, 2018, 23, 1436-1445.	3.7	9
295	Assessment of proliferating cell nuclear antigen in nasopharyngeal carcinoma tissue and its relation to clinical findings. Oral Oncology, 1997, 33, 13-18.	1.5	8
296	Costâ€ e ffectiveness of Screening for Nasopharyngeal Carcinoma among Asian American Men in the United States. Otolaryngology - Head and Neck Surgery, 2019, 161, 82-90.	1.9	8
297	Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. Radiotherapy and Oncology, 2022, 167, 179-186.	0.6	8
298	Shift detection discrepancy between ExacTrac Dynamic system and coneâ€beam computed tomography. Journal of Applied Clinical Medical Physics, 2022, 23, e13567.	1.9	8
299	A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. Acta Oncológica, 2004, 43, 245-251.	1.8	7
300	Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. BMC Cancer, 2006, 6, 259.	2.6	7
301	Viral co-infections and paraproteins in HIV: effect on development of hematological malignancies. Annals of Hematology, 2016, 95, 575-580.	1.8	7
302	Nasopharyngeal carcinoma: relationship between invasion of the prevertebral space and distant metastases. European Archives of Oto-Rhino-Laryngology, 2018, 275, 497-505.	1.6	7
303	Clinical outcomes of post-operative locoregional radiotherapy in pre-menopausal and post-menopausal Chinese women with breast cancer. Radiotherapy and Oncology, 2000, 54, 201-208.	0.6	6
304	Quantitative correlation of cytokeratin 19 mRNA level in peripheral blood with disease stage and metastasis in breast cancer patients: potential prognostic implications. International Journal of Oncology, 2001, 18, 633-8.	3.3	6
305	Head and neck cancer: treatment of nasopharyngeal cancer. Annals of Oncology, 2005, 16, ii265-ii268.	1.2	6
306	Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal Cancer. Journal of Oncology, 2009, 2009, 1-6.	1.3	6

#	Article	IF	CITATIONS
307	A novel compound 6Dâ€offset simulating phantom and quality assurance program for stereotactic imageâ€guided radiation therapy system. Journal of Applied Clinical Medical Physics, 2013, 14, 100-116.	1.9	6
308	Retrospective study of the prevalence and progression of monoclonal gammopathy in HIV positive versus HIV negative patients. Hematological Oncology, 2017, 35, 64-68.	1.7	6
309	The Use of Post-ablation Stimulated Thyroglobulin in Predicting Clinical Outcomes in Differentiated Thyroid Carcinoma – What Cut-off Values Should We Use?. Clinical Oncology, 2019, 31, e11-e20.	1.4	6
310	Analysis of Hepatocellular Carcinoma Stereotactic Body Radiation Therapy Dose Prescription Method Using Uncomplicated Tumor Control Probability Model. Advances in Radiation Oncology, 2021, 6, 100739.	1.2	6
311	Efficacy and toxicity of intensity-modulated radiation therapy for prostate cancer in Chinese patients. Hong Kong Medical Journal, 2013, 19, 407-15.	0.1	6
312	Automated extraction protocol for quantification of SARS-Coronavirus RNA in serum: an evaluation study. BMC Infectious Diseases, 2006, 6, 20.	2.9	5
313	A Novel Application of Plasma and Cerebrospinal Fluid Level of Epstein Barr Virus DNA in the Diagnosis of Leptomeningeal Metastasis from Nasopharyngeal Carcinoma. Oncology, 2008, 74, 119-122.	1.9	5
314	Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 270-280.	3.8	5
315	The expanding universe of checkpoint inhibitors for nasopharyngeal cancer. Nature Medicine, 2021, 27, 1512-1513.	30.7	5
316	Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients Journal of Clinical Oncology, 2014, 32, 6022-6022.	1.6	5
317	Accomplishments in 2007 in the management of hepatobiliary cancers. Gastrointestinal Cancer Research: GCR, 2008, 2, S25-31.	0.7	5
318	Hypersensitivity to dexamethasone BMJ: British Medical Journal, 1993, 306, 109-109.	2.3	4
319	Retrospective study of the incidence and patterns of arterial and venous thrombosis in Chinese <i>versus</i> African American patients with multiple myeloma. British Journal of Haematology, 2017, 176, 315-317.	2.5	4
320	Abstract 1638: Preclinical evaluation of the PI3K inhibitor BEZ235 in nasopharyngeal carcinoma cell lines. , 2010, , .		4
321	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiotherapy (CRT) Journal of Clinical Oncology, 2012, 30, 5511-5511.	1.6	4
322	Complete small bowel obstruction caused by metastasis from primary nasopharyngeal carcinoma. Rare Tumors, 2009, 1, e7.	0.6	4
323	Targeting the polycomb repressive complex-2 related proteins with novel combinational strategies for nasopharyngeal carcinoma. American Journal of Cancer Research, 2020, 10, 3267-3284.	1.4	4
324	Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma. Clinical Cancer Research, 2022, 28, 2679-2689.	7.0	4

#	Article	IF	CITATIONS
325	Primary Mediastinal Malignant Germ Cell Tumour Single Institution Experience in Chinese Patients and correlation with specific alpha-fetoprotein bands. Acta Oncológica, 1996, 35, 221-227.	1.8	3
326	Utilization and Monitoring of Aminoglycosides in Oncology Patients at a Hong Kong Government Hospital. Annals of Pharmacotherapy, 1999, 33, 646-649.	1.9	3
327	Case of chlorambucil-induced seizure. Internal Medicine Journal, 2006, 36, 683-684.	0.8	3
328	An unusual cause of superior vena cava obstruction. Thorax, 2006, 61, 182-182.	5.6	3
329	Sequential Chemotherapy with Combination Irinotecan and Cisplatin Followed by Docetaxel for Treatment-NaÃ ⁻ ve Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 838-844.	1.1	3
330	52LBA Final report of NPC-9902 trial on therapeutic gain and late toxicities by concurrent-adjuvant chemotherapy and/or accelerated fractionation for T3-4N0-1M0 nasopharyngeal carcinoma. European Journal of Cancer, Supplement, 2009, 7, 22.	2.2	3
331	6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma – a Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG). European Journal of Cancer, 2011, 47, S470-S471.	2.8	3
332	Advanced technologies for studying circulating tumor cells at the protein level. Expert Review of Proteomics, 2013, 10, 579-589.	3.0	3
333	The effect of the magnetic fields from three different configurations of the MRIgRT systems on the dose deposition from lateral opposing photon beams in a laryngeal geometry – A Monte Carlo study. Radiation Medicine and Protection, 2021, 2, 103-111.	0.8	3
334	Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma Journal of Clinical Oncology, 2010, 28, 2585-2585.	1.6	3
335	Long-term treatment outcome of nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT) Journal of Clinical Oncology, 2010, 28, 5582-5582.	1.6	3
336	A Prospective Study of Combined m-BACOD Chemotherapy and Radiotherapy for Aggressive Nasal NK/T-Cell Lymphoma Blood, 2005, 106, 2680-2680.	1.4	3
337	In vitro uptake of bromodeoxyuridine by human nasopharyngeal carcinoma (NPC) and its relation to clinical findings. European Journal of Cancer Part B, Oral Oncology, 1996, 32, 50-54.	0.9	2
338	Serum proteomic pattern for predicting recurrence of undifferentiated nasopharyngeal carcinoma after radiotherapy. Clinical Proteomics, 2004, 1, 365-373.	2.1	2
339	Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma. Acta OncolÃ ³ gica, 2005, 44, 177-179.	1.8	2
340	Accelerated fractionation radiotherapy and late intensification with 2 intraâ€arterial cisplatin infusions for locally advanced head and neck squamous cell carcinoma. Head and Neck, 2010, 32, 913-920.	2.0	2
341	Towards magnetic-field-modulated radiotherapy (MagMRT) with an MR-LINAC—a Monte Carlo study. Physics in Medicine and Biology, 2021, 66, 205014	3.0	2
342	Abstract 4602: Preclinical evaluation of the AKT inhibitor MK2206 in nasopharyngeal carcinoma cell lines. Cancer Research, 2012, 72, 4602-4602.	0.9	2

#	Article	IF	CITATIONS
343	Subcutaneous amifostine for reduction of radiation xerostomia in nasopharynx cancer: A prospective randomised study. Journal of Clinical Oncology, 2005, 23, 8043-8043.	1.6	2
344	Therapeutic vaccination with modified vaccinia Ankara (MVA) encoding Epstein-Barr virus (EBV) target antigens in EBV+ nasopharyngeal carcinoma (NPC). Journal of Clinical Oncology, 2008, 26, 3052-3052.	1.6	2
345	A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens Journal of Clinical Oncology, 2011, 29, 2592-2592.	1.6	2
346	A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) Journal of Clinical Oncology, 2015, 33, 6031-6031.	1.6	2
347	Non-surgical treatment of lung cancer: personalised stereotactic ablative radiotherapy. Hong Kong Medical Journal, 2014, 20, 529-36.	0.1	2
348	Netilmicin pharmacokinetics in Hong Kong Chinese cancer patients. British Journal of Clinical Pharmacology, 1999, 48, 33-35.	2.4	1
349	Transcriptional profiling of tumor biopsies in oncology trials—a â€~window' of opportunity for evaluating new drugs in nasopharyngeal cancer?. Annals of Oncology, 2006, 17, 1611-1613.	1.2	1
350	The Evolving Role of Systemic Therapy in Nasopharyngeal Carcinoma: Current Strategies and Perspectives. Advances in Experimental Medicine and Biology, 2013, , 149-172.	1.6	1
351	Toward Improving Treatment Planning Quality and Efficiency Using Knowledge Engineering and Autoplanning: A Study Based on NRG-HN001 Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2016, 96, E656-E657.	0.8	1
352	Abstract 3773: Preclinical evaluation of the CDK4/6 inhibitor LEE011 in nasopharyngeal carcinoma (NPC) cell lines. , 2016, , .		1
353	Prognostic system for hepatitis B virus (HBV)-related hepatocellular carcinoma- Prospective validation of the Chinese University Prognostic Index. Journal of Clinical Oncology, 2008, 26, 4591-4591.	1.6	1
354	The effect of cisplatin dose administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma Journal of Clinical Oncology, 2011, 29, 5532-5532.	1.6	1
355	The expression of frizzled-3 receptor in colorectal cancer and colorectal adenoma Journal of Clinical Oncology, 2011, 29, 444-444.	1.6	1
356	Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG) Journal of Clinical Oncology, 2012, 30, 259-259.	1.6	1
357	A phase IB trial of 5-azacitidine (5AC) and suberoylanilide hydroxamic acid (SAHA) in patients with metastatic or locally recurrent nasopharyngeal carcinoma (NPC) and NK-T cell lymphoma Journal of Clinical Oncology, 2013, 31, e17017-e17017.	1.6	1
358	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial Journal of Clinical Oncology, 2014, 32, 6029-6029.	1.6	1
359	The association between serum folate level and toxicity of capecitabine Journal of Clinical Oncology, 2016, 34, 3566-3566.	1.6	1
360	The effect on tumour control probability of using AXB algorithm in replacement of AAA for SBRT of hepatocellular carcinoma located at lung–liver boundary region. BJR Open, 2021, 3, 20210041.	0.6	1

#	Article	IF	CITATIONS
361	The significance of serum interleukin-10 on the outcome of unresectable hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2011, 29, 205-205.	1.6	1
362	Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modified XELOX in the first-line treatment of metastatic colorectal cancer (mCRC): Correlation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFa) Journal of Clinical Oncology, 2013, 31, 425-425.	1.6	1
363	SU-C-137-03: Inter-Machine Comparison of Volumetric Intensity Modulated Arc Therapy (VIMAT) Delivery Based On Trajectory Log Analysis. Medical Physics, 2013, 40, 85-85.	3.0	1
364	Retrospective Study of the Incidence and Risk Factors for Hematological Malignancies in Patients with Hepatitis B Virus Infection. Blood, 2014, 124, 5403-5403.	1.4	1
365	Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial Journal of Clinical Oncology, 2019, 37, 6024-6024.	1.6	1
366	Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer. Current Oncology, 2022, 29, 27-37.	2.2	1
367	Quantitative analysis of circulating tumour cells in breast cancer patients using reverse transcriptase polymerase chain reaction. European Journal of Cancer, 1999, 35, S90.	2.8	0
368	A phase II study of gemcitabine plus oral etoposide (GOE) in treatment of advanced non-small cell lung cancer. European Journal of Cancer, 1999, 35, S255.	2.8	0
369	Nonplatinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. Clinical Pulmonary Medicine, 2003, 10, 143-153.	0.3	0
370	Immunomodulatory Effects of Yunzhi-Danshen on Nasopharyngeal Carcinoma Patients. Journal of Allergy and Clinical Immunology, 2006, 117, S202.	2.9	0
371	Patterns of Local Failure Following Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma: Predominance of Within-Field Failure. International Journal of Radiation Oncology Biology Physics, 2007, 69, S413-S414.	0.8	0
372	The KRAB domain-containing zinc finger protein ZNF382 is a potent tumor suppressor with frequent epigenetic inactivation in nasopharyngeal, esophageal and other carcinomas. Cell Biology International, 2008, 32, S5-S5.	3.0	0
373	Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments – CORRIGENDUM. Expert Reviews in Molecular Medicine, 2011, 13, .	3.9	Ο
374	Geometric Accuracy Verification of a Respiratory Gating System Using Gated KV-CBCT and Gated MV-CBCT. International Journal of Radiation Oncology Biology Physics, 2013, 87, S677.	0.8	0
375	2870 Prospective evaluation of both plasma Epstein Barr Virus (EBV) DNA clearance and fludeoxyglucose-positron emission tomography (PET-CT) as a dual-endpoint in predicting early response and survival of patients undergoing chemotherapy (chemo) for advanced nasopharyngeal carcinoma (NPC) (NCT01365208). European Journal of Cancer, 2015, 51, S580.	2.8	0
376	Axitinib in recurrent or metastatic nasopharyngeal carcinoma (NPC): final result of a phase 2 clinical trial with pharmacokinetic (PK) correlation. Annals of Oncology, 2016, 27, vi332.	1.2	0
377	Cost-Effectiveness of Screening for Nasopharyngeal Carcinoma with Plasma Epstein-Barr Virus DNA. International Journal of Radiation Oncology Biology Physics, 2018, 102, e401.	0.8	0
378	A double-blind placebo-control randomized study of the efficacy of Chinese herbal medicine (CHM) in reduction of cytotoxic chemotherapy-induced toxicity. Journal of Clinical Oncology, 2005, 23, 8157-8157.	1.6	0

#	Article	IF	CITATIONS
379	Serial alpha-feto protein in predicting radiological response and overall survival of patient with inoperable hepatocellular carcinoma (HCC) during chemotherapy. Journal of Clinical Oncology, 2008, 26, 4602-4602.	1.6	0
380	Dose-volume analysis of radiation dermatitis among nasopharyngeal carcinoma patients treated with comcurrent cetuximab-cisplatin and intensity-modulated radiotherapy. Journal of Clinical Oncology, 2008, 26, 17015-17015.	1.6	0
381	Nasopharynx. Medical Radiology, 2009, , 57-73.	0.1	0
382	Drug Therapy for Nasopharyngeal Carcinoma: Cytotoxic and Targeted Therapy. Medical Radiology, 2010, , 149-160.	0.1	0
383	The impact of antiviral therapy on the outcome of hepatitis B viral (HBV)-related hepatocellular carcinoma (HCC) detected in surveillance prorgram Journal of Clinical Oncology, 2010, 28, 4028-4028.	1.6	0
384	Abstract 2191: The Wnt/DVL signaling antagonist DACT2 is a pro-apoptotic tumor suppressor epigenetically silenced in multiple tumors and inhibits tumor cell proliferation and migration. , 2011, , .		0
385	Abstract 1006: TP53-induced glycolysis and apoptosis regulator (TIGAR) induces NADPH production and growth in nasopharyngeal carcinoma cells. , 2011, , .		0
386	Abstract 2190:ADAMTS8at 11q25 is a tumor suppressor antagonizing Ras-signaling and methylated in multiple carcinomas. , 2011, , .		0
387	Quantitation of circulating methylated RASSF1A in prognostication and monitoring of treatment response in unresectable hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2011, 29, 4058-4058.	1.6	0
388	A UK-based phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens Journal of Clinical Oncology, 2011, 29, e13028-e13028.	1.6	0
389	Abstract 2811: Preclinical evaluation of combined TKI258 and RAD001 in hepatocellular carcinoma. , 2012, , .		0
390	Abstract 505: Jagged 2 knockdown inhibits invasion in colorectal cancer cell lines. , 2012, , .		0
391	Predictive biomarkers of response to cetuximab in Chinese patients with metastatic colorectal cancer Journal of Clinical Oncology, 2012, 30, e14085-e14085.	1.6	0
392	A randomized study on lipiodal ethanol mixture (LEM) versus transarterial chemoembolization (TACE) for treatment of hepatocellular carcinoma (HCC): Report of a preplanned interim analysis Journal of Clinical Oncology, 2012, 30, e14528-e14528.	1.6	0
393	SU-E-T-94: Surface Dose Characteristics of Flattened and Flattening Filter Free Megavoltage Photon Beam. Medical Physics, 2013, 40, 225-225.	3.0	0
394	SU-E-J-119: Geometric Accuracy Verification for Gated RapidArc Using Gated CBCT Reconstructed From Continuously Triggered KV Images. Medical Physics, 2013, 40, 178-178.	3.0	0
395	Abstract B273: Multicenter Phase II study of MK-2206 in previously treated patients (pts) with recurrent and metastatic nasopharyngeal carcinoma (NPC): Mayo Clinic Phase II Consortium (Protocol: MC1079) , 2013, , .		0
396	A joint United Kingdom (UK) and Hong Kong (HK) study to determine prognostic factors for hepatocellular carcinoma (HCC) undergoing curative and palliative treatment Journal of Clinical Oncology, 2014, 32, 181-181.	1.6	0

#	Article	IF	CITATIONS
397	Identifying an early indicator of drug efficacy in patients (pts) with metastatic colorectal cancer (mCRC): A prospective evaluation of circulating tumor cells (CTC), 18F-fluorodeoxyglucose positron-emission tomography (PET), and the RECIST criteria Journal of Clinical Oncology, 2014, 32, 3582-3582.	1.6	0
398	Abstract 5499: Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC) using 3D cell culture system. , 2014, , .		0
399	Abstract 5003: Functional significance of TIGAR expression in nasopharyngeal carcinoma. , 2014, , .		0
400	A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response Journal of Clinical Oncology, 2015, 33, 4073-4073.	1.6	0
401	SUâ€Eâ€Tâ€727: The Application of Regularizationâ€Based Multiâ€Channel Radiochromic Film Dosimetry for Patientâ€Specific QA of Stereotactic Body Radiation Therapy (SBRT) Treatment. Medical Physics, 2015, 42, 3504-3504.	3.0	0
402	TU-F-CAMPUS-J-01: A Formulation of 4D Treatment Planning for Tumour Tracking Volumetric Modulated Arc Therapy for Lung Cancer. Medical Physics, 2015, 42, 3645-3645.	3.0	0
403	SUâ€Eâ€Tâ€565: Multiple Channel Radiochromic Film Calibration with Spatial Dose Gradient Regularization. Medical Physics, 2015, 42, 3465-3466.	3.0	0
404	SUâ€Eâ€Tâ€422: Fast Analytical Beamlet Optimization for Volumetric Intensityâ€Modulated Arc Therapy. Medical Physics, 2015, 42, 3431-3431.	3.0	0
405	Abstract 5594: Progression of paraproteinemia in HIV-positive versus HIV-negative patients. , 2015, , .		0
406	Novel Tumor Suppressive Role of the RAS GTPase-Activating Protein RASA5 to RAS Signaling Perturbation in Human Carcinomas. SSRN Electronic Journal, 0, , .	0.4	0
407	Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for patients with early-stage localized prostate cancer: One-year late toxicity results from a prospective randomized phase II study Journal of Clinical Oncology, 2019, 37, 27-27.	1.6	0